Anabolic bone medications

Sharing is caring!

How effective are the currently available anabolic bone agents?

Teriparatide (Forteo) is a 34 amino acid fragment of intact PTH that retains the ability to bind to and activate PTH receptors on osteoblasts and osteoblast precursors. It is self-administered daily at a 20 mcg/day dose SC for 18 to 24 months. In trials, teriparatide increased lumbar spine bone mass by 9% to 13% and hip bone mass by 2.5% to 5% while decreasing the relative risk of new vertebral fractures by 65% and nonvertebral fractures by 50%. The most common side effects are similar to placebo and include headache, nausea, arthralgias, orthostasis, and flushing. Teriparatide must be refrigerated for the duration of its use; it becomes inactivated if left unrefrigerated for over 24 hours.

Abaloparatide (Tymlos) is a 34 amino acid fragment of PTHrP that also activates osteoblast recruitment and activity. It is self-injected at an 80 mcg SQ daily dose, and its use is limited to 24 months. Spine BMD has been shown to increase by 10.4% and hip BMD by 4% compared with placebo. In a head-to-head trial against teriparatide, abaloparatide reduced new vertebral fractures by 86%, nonvertebral fractures by 43%, and major osteoporosis fractures by 70% (the reduction in major osteoporosis fractures was statistically significantly better than teriparatide). Side effects are similar to those reported with teriparatide. Abaloparatide does not require refrigeration.

Sharing is caring!


Sign up to receive the trending updates and tons of Health Tips

Join SeekhealthZ and never miss the latest health information